Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.

@article{Bjarnason2015DovitinibT,
  title={Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.},
  author={Georg Bjarnason and Palma Giglione and Wanda Liguigli and Chiara Paglino},
  journal={Future oncology},
  year={2015},
  volume={11 1},
  pages={
          39-50
        }
}
Dovitinib is an oral multikinase inhibitor targeting FGF receptors, PDGF receptors and VEGF receptors. Its activity against FGF receptors suggests its usefulness in treating cancers after the failure of VEGF/VEGF receptor-targeting agents. The identified dose and schedule to be used in further studies was 500 mg orally for 5 days on and 2 days off. Biological considerations and the results achieved in a Phase I/II trial suggested its activity in advanced renal cell carcinoma patients pretreated… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

  • Critical reviews in oncology/hematology
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Phase 3 trial of dovitinib versus sorafenib for thirdline targeted treatment of patients with metastatic renal cell carcinoma : an open - label , randomized Phase 3 trial

RJ Motzer, C Porta, N Vogelzang
  • Lancet Oncol .
  • 2014